About 40% of patients with diabetes could develop CKD [4], and it could be already present at diagnosis especially in patients with type 2 diabetes [5]
Scientific Data: In the SURPASS trials, tirzepatide showed higher rates of gastrointestinal side effects compared to semaglutide, but these were generally temporary and resolved as treatment continued
Remember, the path to a healthier you starts with education, empowerment, and the right tools by your side.
GHK-Cu is a naturally occurring copper-complexed tripeptide (Glycyl-L-Histidyl-L-Lysine + Cu) commonly referenced in scientific literature for laboratory and preclinical research applications
This length allows the medication to pass through several layers of skin and fat
In my clinical experience, the pattern is similar for both medications: Weeks 14: Nausea is most common, especially after meals